Nothing fishy about this appointment.
Codiak has enjoyed enormous growth and interest recently and I assume Mr Haddock has been partly responsible.
PYC is quietly assembling the "Dream Team" (IMO). This team should open doors and aid the process through clinical trials and, hopefully FDA approval for conditions currently without treatment. That is, unless PYC gets taken out by an irresistable offer beforehand.
Ann: PYC Appoints U.S. Biopharma Exec Jason Haddock to its Board, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.035(2.70%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.26 | $2.681M | 2.075M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3081 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.11pm 28/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |